# Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections

> **NCT03331445** · PHASE2 · TERMINATED · sponsor: **Chris Miller** · enrollment: 13 (actual)

## Conditions studied

- Respiratory Tract Infections
- Corona Virus Infection

## Interventions

- **DRUG:** Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation

## Key facts

- **NCT ID:** NCT03331445
- **Lead sponsor:** Chris Miller
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-24
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Covid Incidence too low and Funding Completed
- **Last updated:** 2021-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331445, "Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT03331445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*